1 week Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow Investor's Business Daily

Eli Lilly stock fell on lowered Q4 guidance amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs.
The post Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow appeared first on Investor's Business Daily.